Month: September 2020

La Société de Gestion AGF Limitée conclut une entente définitive avec SAF GroupTORONTO , 23 sept. 2020 (GLOBE NEWSWIRE) — La Société de Gestion AGF Limitée (« AGF ») a annoncé aujourd’hui qu’elle renforce son engagement à l’égard des investissements alternatifs privés, en élargissant son partenariat avec SAF Group (« SAF »), et se donne l’occasion d’accroître sa participation avec le temps.« Le capital que nous avons reçu à la suite de la conclusion de la fusion de Smith & Williamson et de Tilney permet à AGF de redéployer du capital de plusieurs façons, notamment pour saisir de nouvelles occasions de croissance telles que celles dans le domaine des alternatifs privés. Grâce à notre partenariat élargi avec SAF, nous cherchons à offrir à nos clients de partout dans le monde des occasions supplémentaires et peu communes d’investissement...

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271 (CK-271). CK-271 is a second cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM).“This Phase 1 study of CK-271 builds on our longstanding approach to advance back-up and follow-on compounds consistent with our portfolio management strategy,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “As we expand the development program for CK-274 currently in Phase 2, we plan to characterize this second cardiac myosin inhibitor to determine how it may align...

VANCOUVER, British Columbia, Sept. 23, 2020 (GLOBE NEWSWIRE) — BC Craft Supply Co. Ltd. (the “Company” or “BC Craft”) (CSE:CRFT) (FSE:ZZD1) is pleased to announce a new and exciting BC cultivar into its supply chain; Island Pinkhead from newly licensed micro cultivator Dunn Cannabis Inc. (“Dunn Cannabis”). 20.5kg of Island Pinkhead has been purchased by BC Craft and shipped to Indiva Limited (“Indiva”) (TSXV:NDVA) (OTCQX:NDVAF) for processing under a master processing agreement (“MPA”) that was announced on May 13, 2020. Under the MPA, the dried flower will be processed by Indiva’s new premium brand, Artisan Batch, and packaged in beautiful 3.5 gram jars. Artisan Batch features strains from craft and micro growers across Canada, who pride themselves on the quality, potency, and terpene profile of their strains.Dunn Cannabis is one...

HIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 study (NCT03335371) that support the clinical potential of TTP399 as an oral adjunctive therapy in type 1 diabetes (T1D). Newly reported data provide additional evidence suggesting that TTP399 does not increase the risk of diabetic ketoacidosis (DKA), a serious and potentially life-threatening complication that occurs in patients with T1D, due to its unique mechanism of action. DKA is a known side-effect and shortcoming of several investigational oral therapies that have been advanced for T1D, and TTP399’s positive impact on ketone levels is a point of important differentiation. The company also presented additional data from the Simplici-T1 study confirming that treatment with...

ST. PETERSBURG, FL, Sept. 23, 2020 (GLOBE NEWSWIRE) — Global Technologies, Ltd (OTC Pink: GTLL), a holding corporation, which through its subsidiaries, has operations engaged in the online sales of CBD and hemp related products, the acquisition of intellectual property in the safety and security space and as a portal for entrepreneurs to provide immediate access to live shopping, e-commerce, product placement in brick and mortar retail outlets and logistics is pleased to announce that the Company has taken steps to expand its revenue stream through an acquisition and vendor approval.On September 3, 2020, the Company entered into a Commitment to be Bound by the Amended Operating Agreement to Effect Transfer of Membership Interest in order to facilitate the transfer of 25 Membership Units (the “Units”) issued by Global Clean Solutions,...

EVLI BANK PLC STOCK EXCHANGE RELEASE SEPTEMBER 23, 2020, AT 2.30 PM (EST/EEST)The Board of Directors of Evli Bank Plc has on September 1, 2020 decided on a directed share issue for the reward payment of Evli Bank Plc’s Restricted Share Plan 2017.In the share issue, 46,389 Evli Bank Plc’s Series B shares have on September 23, 2020 been issued and conveyed without consideration to the key persons participating in the plan according to the terms and conditions of the plan.The decision on the directed share issue is based on the authorization granted to the Board of Directors by the Annual General Meeting of Shareholders held on March 9, 2020. After the directed share issue, the company holds 328,998 own shares.Evli Bank has informed about the Restricted Share Plan 2017 in a stock exchange release on September 5, 2017.EVLI BANK PLCFor...

Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patientsROCKVILLE, MD, Sept. 23, 2020 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, highlighting the development of MGC018, the Company’s investigational antibody-drug conjugate (ADC) targeting B7-H3 for the treatment of solid tumors.B7-H3 has been identified as a cell surface protein with limited expression on normal tissues but over-expressed on the epithelium and...

Company Announcement No. 23 Aalborg, 23. September 2020 Seluxit presents an annual report, demonstrating the ability to deliver on revenue and result – while creating an interesting pipeline of products for future growth.Daniel Lux, CEO:“Some of the results which our dedicated staff and great partners have created and which I would like to highlight are:175.000 delivered radio modules for Smart Meters to the German marketSLX Heartbeat, a new product to monitor heart starters was developed and first installations were made in collaboration with our partners Rapid Prototyping Kit – launch of our standard development tools and a webshop where these can be bought directlyA growth in revenue by 17% despite a challenging second half of the fiscal yearThe goal for 2019/20 was to create business visibility in the market, grow our...

Selskabsmeddelelse nr. 23 Aalborg, 23. september 2020 Seluxit præsenterer en årsrapport, der demonstrerer evnen til at levere omsætning og resultat – samtidig med, at der skabes en interessant pipeline af produkter til fremtidig vækst.Daniel Lux, CEO udtaler:”Nogle af de resultater, som vores dedikerede medarbejdere og gode partnere har skabt, og som jeg gerne vil fremhæve, er:175.000 leverede radiomoduler til Smart Meters til det tyske markedSLX Heartbeat, et nyt produkt til overvågning af hjertestartere blev udviklet, og de første installationer er foretaget i samarbejde med vores partnereRapid Prototyping Kit – lancering af vores standardudviklingsværktøjer og en webshop, hvor disse kan købes direkteEn vækst i omsætningen med 17%, på trods af en udfordrende anden halvdel af regnskabsåretMålet for 2019/20 var at skabe forretningssynlighed...

ALPHARETTA, Ga., Sept. 23, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today several clinical data presentations were given at the virtual 53rd Annual Scientific Meeting of The Retina Society.Clearside also announced that data from the Company’s Phase 2 clinical trial in diabetic macular edema (DME) was published in Ophthalmology Retina and can be accessed here. The trial, entitled TYBEE, evaluated the investigational drug XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) when used with intravitreally administered aflibercept in patients with DME over a 6-month evaluation period. This early data suggests that, if approved,...